公司库 > 公司详情页

$ 20.76

+1.08(5.49%)

04-24 16:08

Voyager Therapeutics

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
最高：20.95今开：19.69成交量：24.04万股换手：0.65%
最低：19.62昨收：19.68成交额：489.08万振幅：6.73%
52周最高：24.24量比：0.65市盈率(TTM)：亏损市净率：14.42
52周最低：7.76委比：-81.82%市盈率(静)：亏损市销率：89.79
每股收益：-2.75股息：--每手股数：1总市值：7.65亿
每股净资产：1.44股息率：--最小价差：0.01总股本：3683.06万
机构持股：--Beta：2.83空头回补天数：3.07货币单位：USD
最新获投

战略投资 $6500万

2019-02-25
最新动态
暂无数据
五力模型
财务指标
单位:美元
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
流动资产
2.00亿
2.21亿
1.72亿
1.28亿
1.45亿
现金及短期投资
1.96亿
2.18亿
1.69亿
1.26亿
1.41亿
短期应收账款
--
--
145.20万
--
--
存货
--
--
--
--
--
其他流动资产
412.20万
243.30万
128.60万
260.40万
340.30万
非流动资产
1,441.80万
1,439.50万
1,268.70万
1,272.40万
1,368.80万
厂房及设备净资产
1,224.40万
1,145.80万
1,028.30万
1,055.80万
1,067.40万
项目总投资及垫款
159.50万
132.00万
180.00万
96.00万
148.00万
长期应收票据
--
--
--
--
--
无形资产
--
--
--
--
--
递延所得税资产
--
--
--
--
--
其他资产
57.90万
161.70万
60.40万
120.60万
153.40万
合计总资产
2.15亿
2.35亿
1.84亿
1.41亿
1.58亿
流动负债
2,909.50万
3,094.00万
1,589.70万
2,094.10万
1,183.60万
短期债务（含部分LTD）
--
--
--
--
--
应付账款
155.80万
137.20万
102.00万
91.10万
30.70万
应付所得税
--
--
--
--
--
其他流动负债
2,753.70万
2,956.80万
1,487.70万
2,003.00万
1,152.90万
非流动负债
1.04亿
1.06亿
3,452.90万
3,476.80万
4,128.70万
长期负债
--
--
--
--
--
拨备风险及费用
--
--
--
--
--
递延所得税负债
--
--
--
--
--
其他负债
1.04亿
1.06亿
3,452.90万
3,476.80万
4,128.70万
合计总负债
1.33亿
1.37亿
5,042.60万
5,570.90万
5,312.30万
股东权益合计
8,197.20万
9,829.30万
1.34亿
8,520.60万
1.05亿
非股权储备
--
--
--
--
--
优先股-账面价值
0.00
0.00
0.00
0.00
0.00
普通股权益（合计）
8,197.20万
9,829.30万
1.34亿
8,520.60万
1.05亿
累计少数股东权益
--
--
--
--
--
权益总额
8,197.20万
9,829.30万
1.34亿
8,520.60万
1.05亿
负债与股东权益合计
2.15亿
2.35亿
1.84亿
1.41亿
1.58亿
每股账面价值
2.56
3.08
4.25
3.25
4.05
每股账面价值-有形
2.56
3.08
4.25
3.25
4.05
单位:美元
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
营业总收入
257.50万
94.20万
634.50万
114.80万
117.70万
-营业成本
257.50万
94.20万
634.50万
114.80万
117.70万
毛利
--
--
--
--
--
-销售管理及行政费用
2,775.30万
2,157.90万
1,825.70万
2,407.00万
1,940.70万
-其他运营费用
--
--
--
--
--
计息税前利润
-2,569.40万
-2,109.30万
-1,234.80万
-2,335.50万
-1,863.90万
+非经营收入(支出)
15.30万
98.70万
55.00万
30.90万
-4.20万
-非经常性支出
--
--
--
30.00万
--
-利息支出
--
--
--
--
--
税前净利润
-2,554.10万
-2,010.60万
-1,179.80万
-2,334.60万
-1,868.10万
-所得税
--
-18.00万
-3.10万
--
19.50万
+其他税后调整
0.00
0.00
0.00
0.00
0.00
+联署公司盈利权益
--
--
--
--
--
合并净利润
-2,554.10万
-1,992.60万
-1,176.70万
-2,334.60万
-1,887.60万
-少数股东权益开支
--
--
--
--
--
净利润
-2,554.10万
-1,992.60万
-1,176.70万
-2,334.60万
-1,887.60万
-优先股股息
--
--
--
--
--
一般可用收入净利润
-2,554.10万
-1,992.60万
-1,176.70万
-2,334.60万
-1,887.60万
每股基本收益
-0.80
-0.63
-0.40
-0.89
-0.73
摊薄每股收益
-0.80
-0.63
-0.40
-0.89
-0.73
息税折旧摊销前利润
-2,517.80万
-2,063.70万
-1,191.20万
-2,292.20万
-1,823.00万
单位:美元
2017-12-31
2016-12-31
2015-12-31
2014-12-31
净收益
-7,069.80万
-4,019.30万
-2,967.20万
-1,631.70万
+折旧损耗及摊稍
159.50万
61.20万
60.00万
18.40万
+递延税及投资税减免
--
--
--
--
+其他经营基金
937.30万
889.70万
1,395.20万
296.80万
营运资金
-5,973.00万
-3,068.40万
-1,512.00万
-1,316.50万
+特别项目
--
--
--
--
+营运资金变动
-162.00万
-1,179.80万
5,641.90万
124.70万
经营现金流
-6,135.00万
-4,248.20万
4,129.90万
-1,191.80万
资本支出
-398.50万
-502.90万
-103.00万
-298.80万
收购所得净资产
--
--
--
--
固定资产和业务出售收入
--
--
--
--
投资买卖净额
30.40万
5,232.90万
-1.94亿
--
非现金项目
0.00
0.00
0.00
-31.40万
投资现金流
-368.10万
4,730.00万
-1.95亿
-330.20万
发放现金股利
--
--
--
--
股本变动
5,992.00万
51.40万
1.05亿
2,212.00万
发行/削减债务净额
--
--
--
--
其他融资基金
--
--
7,295.50万
--
筹资现金流
5,992.00万
51.40万
1.78亿
2,212.00万
汇率影响
--
--
--
--
杂项基金
--
--
--
--
现金净流动
-511.10万
533.20万
2,427.40万
690.00万
自由现金流
-6,533.50万
-4,751.10万
4,026.90万
-1,490.60万
公司高管
Steven Marc Paul
Steven Marc Paul founded SAGE Therapeutics, Inc. and Tal Medical, Inc. Currently, Dr. Paul is Chairman & Chief Executive Officer for Karuna Pharmaceuticals, Inc. and Executive Chairman for Tal Medical, Inc. He is also Member of Institute of Medicine, Member of National Academy of Sciences, Member of The National Advisory Mental Health Council and Member-Science Board at US Food & Drug Administration and on the board of 13 other companies. Steven Marc Paul previously was Executive Vice President-Science & Technology at Eli Lilly & Co. President at Lilly Research Laboratories and Executive Vice President-Science & Technology at Lilly Industries Ltd. (both are subsidiaries of Eli Lilly & Co.), Medical Director-Commissioned Corps at US Public Health Service, Venture Partner at Third Rock Ventures LLC, Director at BioCrossroads, Scientific Director at National Institute of Mental Health, Member-Advisory Council at National Institute of General Medical Sciences and Professor at Weill Cornell Medical College. Steven Marc Paul received an undergraduate degree from Tulane University (Louisiana) and a doctorate and a graduate degree from Tulane University School of Medicine.
Perry A. Karsen
Perry A. Karsen is a businessperson who has been the head of 8 different companies and currently occupies the position of Executive Chairman for OncoMed Pharmaceuticals, Inc., Chairman for Jounce Therapeutics, Inc., Chairman of Intellia Therapeutics, Inc. and President & Director at Stalar 3, Inc. Mr. Karsen is also on the board of Life Science Foundation, Gladstone Foundation (CA), Voyager Therapeutics, Inc. and The Sonoma Land Trust and Member of Roche Holding AG. In his past career Mr. Karsen was Chairman at Pliant Therapeutics, Inc., Chief Operating Officer & Executive Vice President at Celgene Corp. Chief Executive Officer at Anthrogenesis Corp. Chief Executive Officer of Celgene Cellular Therapeutics and Chief Operations Officer & EVP at Celgene LLC (which are all subsidiaries of Celgene Corp.), General Partner for FirstMark Capital LLC, Senior VP & Head-Worldwide Business Development at Celgene Corp. Chief Executive Officer of Anthrogenesis Corp. Chief Executive Officer at Celgene Cellular Therapeutics and Chief Operations Officer & EVP at Celgene LLC (which are all subsidiaries of Celgene Corp.), VP-Strategic Business Analysis & Development at Bristol-Myers Squibb Co., Commercial Director-Europe Region at Abbott Laboratories, Venture Partner at Third Rock Ventures LLC, President & Chief Executive Officer for Pearl Therapeutics, Inc., Senior Vice President-Business Development at Human Genome Sciences, Inc., Director-Business Development at Genentech, Inc. and Senior Vice President-Sales & Marketing at Zimmer, Inc. Perry A. Karsen received a graduate degree from Duke University, an undergraduate degree from the University of Illinois and an MBA from Kellogg School of Management.
Wendy L. Dixon
Currently, Wendy L. Dixon occupies the position of Chairman at Sesen Bio, Inc. and President at Great Meadow Consulting LLC. She is also on the board of 5 other companies. In her past career Dr. Dixon occupied the position of Principal at West Pharmaceutical Services, Inc., Senior Vice President & President-Marketing at Merck & Co., Inc., Chief Marketing Officer for Bristol-Myers Squibb Co., Principal at Centocor, Inc., Senior Advisor at The Monitor Group, Inc., Principal at Osteotech, Inc. and Principal at Smithkline & French Laboratories US, Inc. She received a graduate degree, a doctorate and an undergraduate degree from the University of Cambridge.
Mark Jay Levin
Mr. Mark J. Levin is a Chairman at Voyager Therapeutics, Inc., a Partner at Third Rock Ventures LLC, a Chairman at Fulcrum Therapeutics, Inc., a Managing Member at TRV GP LLC, a Member at National Academy of Engineering and a Member at Personalized Medicine Coalition. He is on the Board of Directors at Corvia Medical, Inc., NinePoint Medical, Inc. and Partners In Health. Mr. Levin was previously employed as an Independent Director by Foundation Medicine, Inc., a Chief Executive Officer & Director by Millennium Pharmaceuticals, Inc., a Chief Executive Officer by Focal, Inc., a Chief Executive Officer by Tularik, Inc., a Chief Executive Officer by CytoTherapuetics, Inc., a Chief Executive Officer by StemCells, Inc., a Chief Executive Officer by Cell Genesys, Inc., a Partner by Mayfield Fund LLC, a Chief Executive Officer by Abgenix, Inc., a Chairman by Constellation Pharmaceuticals, Inc., a Process Engineer & Project Leader by Eli Lilly & Co., and a Process Engineer & Project Leader by Genentech, Inc. He also served on the board at Blueprint Medicines Corp. and Eleven Biotherapeutics, Inc. He received his graduate degree from Washington University in St. Louis.
Michael John Higgins
Michael John Higgins is on the board of Genocea Biosciences, Inc. and 5 other companies. In his past career he was Chief Operating Officer for Ironwood Pharmaceuticals, Inc., Chief Financial Officer for Boston Business Journal, Group Vice President at Jacobs Engineering Group, Inc. and Director & Vice President at Jacobs One Ltd. (a subsidiary of Jacobs Engineering Group, Inc.), Vice President-Finance & Business Development at Genzyme Corp. and Chief Financial Officer of Procept, Inc. Mr. Higgins received an undergraduate degree from Cornell University, an MBA from Tuck School of Business at Dartmouth and a graduate degree from Dartmouth College.
Steven Marc Paul
Steven Marc Paul founded SAGE Therapeutics, Inc. and Tal Medical, Inc. Currently, Dr. Paul is Chairman & Chief Executive Officer for Karuna Pharmaceuticals, Inc. and Executive Chairman for Tal Medical, Inc. He is also Member of Institute of Medicine, Member of National Academy of Sciences, Member of The National Advisory Mental Health Council and Member-Science Board at US Food & Drug Administration and on the board of 13 other companies. Steven Marc Paul previously was Executive Vice President-Science & Technology at Eli Lilly & Co. President at Lilly Research Laboratories and Executive Vice President-Science & Technology at Lilly Industries Ltd. (both are subsidiaries of Eli Lilly & Co.), Medical Director-Commissioned Corps at US Public Health Service, Venture Partner at Third Rock Ventures LLC, Director at BioCrossroads, Scientific Director at National Institute of Mental Health, Member-Advisory Council at National Institute of General Medical Sciences and Professor at Weill Cornell Medical College. Steven Marc Paul received an undergraduate degree from Tulane University (Louisiana) and a doctorate and a graduate degree from Tulane University School of Medicine.
Perry A. Karsen
Perry A. Karsen is a businessperson who has been the head of 8 different companies and currently occupies the position of Executive Chairman for OncoMed Pharmaceuticals, Inc., Chairman for Jounce Therapeutics, Inc., Chairman of Intellia Therapeutics, Inc. and President & Director at Stalar 3, Inc. Mr. Karsen is also on the board of Life Science Foundation, Gladstone Foundation (CA), Voyager Therapeutics, Inc. and The Sonoma Land Trust and Member of Roche Holding AG. In his past career Mr. Karsen was Chairman at Pliant Therapeutics, Inc., Chief Operating Officer & Executive Vice President at Celgene Corp. Chief Executive Officer at Anthrogenesis Corp. Chief Executive Officer of Celgene Cellular Therapeutics and Chief Operations Officer & EVP at Celgene LLC (which are all subsidiaries of Celgene Corp.), General Partner for FirstMark Capital LLC, Senior VP & Head-Worldwide Business Development at Celgene Corp. Chief Executive Officer of Anthrogenesis Corp. Chief Executive Officer at Celgene Cellular Therapeutics and Chief Operations Officer & EVP at Celgene LLC (which are all subsidiaries of Celgene Corp.), VP-Strategic Business Analysis & Development at Bristol-Myers Squibb Co., Commercial Director-Europe Region at Abbott Laboratories, Venture Partner at Third Rock Ventures LLC, President & Chief Executive Officer for Pearl Therapeutics, Inc., Senior Vice President-Business Development at Human Genome Sciences, Inc., Director-Business Development at Genentech, Inc. and Senior Vice President-Sales & Marketing at Zimmer, Inc. Perry A. Karsen received a graduate degree from Duke University, an undergraduate degree from the University of Illinois and an MBA from Kellogg School of Management.
Wendy L. Dixon
Currently, Wendy L. Dixon occupies the position of Chairman at Sesen Bio, Inc. and President at Great Meadow Consulting LLC. She is also on the board of 5 other companies. In her past career Dr. Dixon occupied the position of Principal at West Pharmaceutical Services, Inc., Senior Vice President & President-Marketing at Merck & Co., Inc., Chief Marketing Officer for Bristol-Myers Squibb Co., Principal at Centocor, Inc., Senior Advisor at The Monitor Group, Inc., Principal at Osteotech, Inc. and Principal at Smithkline & French Laboratories US, Inc. She received a graduate degree, a doctorate and an undergraduate degree from the University of Cambridge.
Mark Jay Levin
Mr. Mark J. Levin is a Chairman at Voyager Therapeutics, Inc., a Partner at Third Rock Ventures LLC, a Chairman at Fulcrum Therapeutics, Inc., a Managing Member at TRV GP LLC, a Member at National Academy of Engineering and a Member at Personalized Medicine Coalition. He is on the Board of Directors at Corvia Medical, Inc., NinePoint Medical, Inc. and Partners In Health. Mr. Levin was previously employed as an Independent Director by Foundation Medicine, Inc., a Chief Executive Officer & Director by Millennium Pharmaceuticals, Inc., a Chief Executive Officer by Focal, Inc., a Chief Executive Officer by Tularik, Inc., a Chief Executive Officer by CytoTherapuetics, Inc., a Chief Executive Officer by StemCells, Inc., a Chief Executive Officer by Cell Genesys, Inc., a Partner by Mayfield Fund LLC, a Chief Executive Officer by Abgenix, Inc., a Chairman by Constellation Pharmaceuticals, Inc., a Process Engineer & Project Leader by Eli Lilly & Co., and a Process Engineer & Project Leader by Genentech, Inc. He also served on the board at Blueprint Medicines Corp. and Eleven Biotherapeutics, Inc. He received his graduate degree from Washington University in St. Louis.
Michael John Higgins
Michael John Higgins is on the board of Genocea Biosciences, Inc. and 5 other companies. In his past career he was Chief Operating Officer for Ironwood Pharmaceuticals, Inc., Chief Financial Officer for Boston Business Journal, Group Vice President at Jacobs Engineering Group, Inc. and Director & Vice President at Jacobs One Ltd. (a subsidiary of Jacobs Engineering Group, Inc.), Vice President-Finance & Business Development at Genzyme Corp. and Chief Financial Officer of Procept, Inc. Mr. Higgins received an undergraduate degree from Cornell University, an MBA from Tuck School of Business at Dartmouth and a graduate degree from Dartmouth College.
高管交易状态
交易日期 交易人 职位 类型 交易份额 价格
2018-04-09
Ravina (Bernard M.D.)
Officer
Sell
2451
18.38
2018-04-09
Ravina (Bernard M.D.)
Officer
Sell
2451
18.38
2018-03-22
Henderson (Jane V)
Officer
Buy
11200
11.97
2018-03-22
Henderson (Jane V)
Officer
Sell
11200
20.52
2018-03-22
Henderson (Jane V)
Officer
Sell
11200
20.52
2018-03-22
Henderson (Jane V)
Officer
Buy
11200
11.97
2018-03-21
Henderson (Jane V)
Officer
Buy
19900
11.97
2018-03-21
Henderson (Jane V)
Officer
Sell
19900
21.07
2018-03-21
Henderson (Jane V)
Officer
Buy
19900
11.97
2018-03-21
Henderson (Jane V)
Officer
Sell
19900
21.07
2018-03-18
Henderson (Jane V)
Officer
Buy
1900
11.97
2018-03-18
Henderson (Jane V)
Officer
Buy
1900
11.97
2018-03-18
Henderson (Jane V)
Officer
Sell
1900
21.76
2018-03-18
Henderson (Jane V)
Officer
Sell
1900
21.76
2018-03-15
Henderson (Jane V)
Officer
Buy
15416
11.97
2018-03-15
Henderson (Jane V)
Officer
Sell
15416
22.15
2018-03-15
Henderson (Jane V)
Officer
Sell
15416
22.15
2018-03-15
Henderson (Jane V)
Officer
Buy
15416
11.97
2018-03-11
Ravina (Bernard M.D.)
Officer
Sell
2451
25.16
2018-03-11
Ravina (Bernard M.D.)
Officer
Sell
2451
25.16
2018-02-26
Sah (Dinah)
Officer
Buy
4376
8.33
2018-02-26
Sah (Dinah)
Officer
Buy
5000
11.09
2018-02-26
Sah (Dinah)
Officer
Buy
2184
7.27
2018-02-26
Sah (Dinah)
Officer
Sell
15623
30.00
2018-02-26
Sah (Dinah)
Officer
Buy
4063
11.83
2018-02-26
Sah (Dinah)
Officer
Buy
5000
11.09
2018-02-26
Sah (Dinah)
Officer
Buy
2184
7.27
2018-02-26
Sah (Dinah)
Officer
Sell
15623
30.00
2018-02-26
Sah (Dinah)
Officer
Buy
4063
11.83
2018-02-26
Sah (Dinah)
Officer
Buy
4376
8.33
查看更多
持股状况
持有者 持有份额 持股比例 份额变化 变化率 报告日期
LAURION CAPITAL MANAGEMENT LP
288963
--
-173942
-37.58%
2018-03-31
Vanguard Group Inc
1083152
--
136057
14.37%
2018-06-30
Casdin Capital, LLC
1135000
--
--
--
2018-06-30
State Street Corp
1229912
--
430966
53.94%
2018-06-30
BlackRock Inc
1245322
--
196509
18.74%
2018-06-30
Fidelity Management and Research Company
1686862
--
-1600189
-48.68%
2018-07-31
BB Biotech AG
2532641
--
540000
27.10%
2018-06-30
Bellevue Asset Management AG
2532641
--
540000
27.10%
2018-06-30
Third Rock Ventures, LLC
18795473
--
8484297
82.28%
2017-12-31
Highline Capital Management LLC
840670
--
840670
--
2018-06-30
Farallon Capital Management, L.L.C.
768157
--
-121843
-13.69%
2018-06-30
Great Point Partners LLC
730010
--
730010
--
2018-06-30
UBS Asset Mgmt Americas Inc
327830
--
60728
22.74%
2018-06-30
Morgan Stanley & Co Inc
359635
--
-60357
-14.37%
2018-06-30
Wells Fargo Advisors, LLC
418222
--
37443
9.83%
2018-06-30
Adage Capital Partners Gp LLC
475000
--
--
--
2018-06-30
Wellington Management Company LLP
518354
--
18344
3.67%
2018-06-30
BlackRock Institutional Trust Company NA
600384
--
211168
54.25%
2018-06-30
Millennium Management LLC
619918
--
1897
0.31%
2018-06-30
Eventide Asset Management, LLC
703425
--
--
--
2018-06-30
Renaissance Technologies Corp
211565
--
211565
--
2018-03-31
AllianceBernstein LP
283830
--
-65677
-18.79%
2018-03-31
AXA Investment Managers UK Ltd
239190
--
-32282
-11.89%
2018-04-30
Tourbillon Capital Partners LP
230000
--
230000
--
2017-12-31
Altrinsic Global Advisors LLC
264927
--
100000
60.63%
2017-12-31
Arctic Fund Management AS
146201
--
--
--
2018-02-28
Northern Trust Investments N A
194102
--
40606
26.45%
2017-12-31
Point72 Asset Management, L.P.
130900
0.50%
130900
--
2017-09-30
Geode Capital Management, LLC
172673
0.55%
31248
22.10%
2017-12-31
Citadel Advisors Llc
250384
0.95%
250384
--
2017-09-30
Partner Fund Management LP
397923
1.52%
-455202
-53.36%
2017-09-30
Dafna Capital Management LLC
157000
0.50%
39741
33.89%
2017-12-31
Baker Bros Advisors LP
237014
0.90%
237014
--
2017-09-30
Deerfield Management Co
117647
0.45%
--
--
2017-09-30
Fiduciary Trust Co
109034
0.42%
--
--
2017-09-30
BlackRock Fund Advisors
939469
3.46%
-5005
-0.53%
2017-12-28
Dimensional Fund Advisors, Inc.
105914
0.40%
7786
7.93%
2017-09-30
Bridgeway Capital Management, Inc
70000
0.27%
70000
--
2017-09-30
Sanofi
2477941
9.94%
2477941
--
2015-12-31
Brookside Capital Management LLC
1514082
5.96%
--
--
2016-09-30
Goldman Sachs Asset Management LP
594422
2.34%
-94823
-13.76%
2016-09-30
J.P. Morgan Investment Management Inc
162003
0.64%
-74922
-31.62%
2016-09-30
GlobeFlex Capital, L.P.
90631
0.36%
50401
125.28%
2016-09-30
Ascend Capital LLC
58267
0.23%
58267
--
2016-09-30
J. P. Morgan Chase Bank NA
49197
0.19%
-2303
-4.47%
2016-09-30
Funds affiliated with Fidelity Management Research Company
1568626
11.00%
--
0.10%
1999-11-30
Aventis, Inc.
2352941
11.00%
--
0.10%
1999-11-30
Third Rock Ventures, L.P.
11061176
11.00%
--
0.40%
1999-11-30
持有者 持有份额 持股比例 份额变化 变化率 报告日期
AST Prudential Growth Allocation Port
48900
0.15%
--
--
2018-07-31
Eventide Healthcare & Life Sciences A
703425
2.19%
--
--
2018-06-30
Vanguard Total Stock Mkt Idx
540453
1.69%
--
--
2018-07-31
iShares Nasdaq Biotechnology
365766
0.97%
-696
-0.19%
2018-09-12
Vanguard Extended Market Idx Inv
261183
0.81%
--
--
2018-07-31
iShares Russell 2000 Growth
203463
0.54%
-196
-0.10%
2018-09-12
JPMorgan US Small Company Instl
188300
0.59%
3700
2.00%
2018-07-31
AST Small-Cap Growth
152147
0.47%
39317
34.85%
2018-07-31
Fidelity Advisor
92133
0.29%
-634526
-87.32%
2018-07-31
Fidelity Spartan
91674
0.29%
--
--
2018-07-31
Bridgeway Ultra-Small Company Market
70000
0.22%
--
--
2018-06-30
CREF Stock R1
71418
0.22%
-1094
-1.51%
2018-07-31
Vanguard Explorer Inv
61401
0.19%
61401
--
2018-06-30
ALPS Medical Breakthroughs ETF
58876
0.16%
--
--
2018-09-14
ClearBridge Small Cap Value A
65400
0.18%
--
--
2018-06-30
iShares Micro-Cap
57782
0.15%
--
--
2018-09-12
Schwab US Small-Cap ETF
54912
0.15%
--
--
2018-09-13
Northern Trust Russell 2000 Index Fund - DC - Non-Lending
51994
0.16%
9
0.02%
2018-07-31
SPDR
910988
2.53%
-8040
-0.87%
2018-09-13
Fidelity
1605562
5.01%
--
--
2018-07-31
Vanguard Health Care ETF
41143
0.13%
80
0.19%
2018-06-30
Schwab Small Cap Index
40000
0.12%
7600
23.46%
2018-06-30
The Vanguard Russell 2000 Growth Index
37964
0.12%
37964
--
2018-06-30
BioShares
37502
0.12%
--
--
2018-07-06
iShares Russell 2000 Value
164368
0.55%
212
0.13%
2018-06-14
DFA US Micro Cap I
29343
0.09%
--
--
2018-02-28
DFA US Small Cap I
34658
0.11%
--
--
2018-02-28
Vanguard Instl Ttl Stk Mkt Idx InstlPls
34952
0.11%
--
--
2018-02-28
RS Technology A
38370
0.12%
38370
--
2017-12-31
BlackRock Russell 2000
28441
0.09%
8066
39.59%
2017-12-31
AXA 2000 Managed Volatility K
22435
0.09%
--
--
2017-10-31
BlackRock Russell 2500
24527
0.09%
13184
116.23%
2017-09-30
PowerShares DWA SmallCap Momentum ETF
48370
0.18%
--
--
2017-12-28
Russell US Small Cap Equity I
14909
0.06%
--
--
2016-12-31
Met Invt Ser JPMorgan Small Cap Val A
17600
0.07%
-3600
-16.98%
2016-12-31
VY JPMorgan Small Cap Core Equity S
20100
0.08%
-1800
-8.22%
2016-12-31
JPMorgan Small Cap Value A
66300
0.25%
--
--
2016-12-31
Goldman Sachs Small/Mid Cap Growth A
277284
1.04%
-292076
-51.30%
2016-12-31